Table of Contents
Program Description
Pulmonary vascular disease (PVD), including pre- and post-capillary pulmonary hypertension, is a spectrum of progressive, symptomatic, and ultimately fatal disorders for which significant advances in treatment have been made. Despite advances in the management of PVD, the mortality rate remains disproportionate. Evaluation and treatment are often delayed until patients present with serious complications. Effective management requires timely recognition, accurate diagnosis, and selection of the different therapeutic options.
Progression to right ventricular dysfunction and finally failure can occur as an acute event in consequences where the pulmonary hypertension develops acutely as with pulmonary embolism, or because of a chronic condition such as pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD), interstitial lung disease, or chronic left sided heart or valvular disease.
Early detection and appropriate management can improve quality of life and may improve survival. Medical therapy has come a long way towards decreasing symptoms, enhancing performance, and improving prognosis, but there is still a long way to go, especially for the broader population of patients with PVD.
This program is tailored to clinical professionals who care for patients with right heart disease, congenital heart disease, pulmonary hypertension, and associated disorders.
At the end of this program, participants should be able to:
- Describe the options for evaluation and management in patients with sarcoid-related pulmonary hypertension (PH).
- Review the management of shock and RV ischemia in patients with advanced PH.
- Discuss considerations for medical therapy and intervention in patients with patent foramen ovale, atrial septal defect, and PH.
- Assess management decisions in a patient with advanced disease and the potential addition of the activin inhibitor class of therapy.
How to Claim Continuing Education Credit
More information on how to claim credit will be coming soon!
Pricing
Earn up to 3 CME Credits!
Registration includes:
- Dinner
- Q&A sessions with experts
- Networking opportunities
| REGULAR RATE | |
|---|---|
| Healthcare Professional | $75 |
| Fellow/Trainee | $50 |
| Industry | $100 |
Refund Policy
NATF will not reimburse any event registrations after October 1, 2024.
Speakers
Event Agenda
*Faculty and agenda subject to change
Registration/Check-in
Welcome and Introductions
Jane Leopold, MD Co-Course Director
Case 1: Evaluation and Management of the Patient with Sarcoidosis and PH
Harrison Farber, MD
Case 1 Q&A
Case 2: Critical Care Management of the Patient with Advanced PH who Develops Shock and RV Ischemia
Bradley Weirtheim, MD
Case 2 Q&A
Case 3: Atrial Septal Defect and Pulmonary Hypertension: Smoking Gun or Innocent Bystander?
Ada Stefanescu, MD, MSc
Case 3 Q&A
Break
Case 4: Management Considerations in the Patient Who’s Responded to Therapy and Now Feels Short of Breath Without Evidence of PH
Paul Yu, MD, PhD
Case 4 Q&A
Case 5: A New Treatment Option: The Activin Inhibitors and Their Impact
Franz Rischard, DO
Case 5 Q&A
Case Reflections and Panel Discussion
Moderated by Jane Leopold, MD
Sponsorship Information
If you are interested in sponsoring the Right Heart Symposium, please contact Aviva Schwartz at [email protected]
GOLD SPONSORS
Merck
SILVER SPONSORS
BRONZE SPONSORS
United Therapeutics
START-UP SPONSORS
Keros Therapeutics
OrphAI
Pharmosa Biopharm Inc.
Roivant/Pulmovant
Tectonic Therapeutic
Event Location
The Palm Restaurant
1 International Place
Boston, MA 02110
Get Directions
Accreditation
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and North American Thrombosis Forum. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Contact Hours: 3
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation
Planning Committee
- Aaron B. Waxman, MD, PhD
- Jane Leopold, MD
- Alexandra Wong, MD
- Bradley Wertheim, MD
- Charlie Lee, PA-C
- Deborah Whalen, APRN, MSN
- Eileen Harder, MD
- Farbod Rahaghi, MD, PhD
- Stephanie Perella, PA-C